90 related articles for article (PubMed ID: 17409891)
1. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer.
Dubey S; Stephenson P; Levy DE; Miller JA; Keller SM; Schiller JH; Johnson DH; Kolesar JM;
J Thorac Oncol; 2006 Jun; 1(5):406-12. PubMed ID: 17409891
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
Tiseo M; Capelletti M; De Palma G; Franciosi V; Cavazzoni A; Mozzoni P; Alfieri RR; Goldoni M; Galetti M; Bortesi B; Bozzetti C; Loprevite M; Boni L; Camisa R; Rindi G; Petronini PG; Ardizzoni A
J Thorac Oncol; 2008 Oct; 3(10):1104-11. PubMed ID: 18827605
[TBL] [Abstract][Full Text] [Related]
3. EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib.
Winther Larsen A; Nissen PH; Meldgaard P; Weber B; Sorensen BS
Lung Cancer; 2014 Sep; 85(3):435-41. PubMed ID: 25017413
[TBL] [Abstract][Full Text] [Related]
4. Shorter EGFR Dinucleotide Repeat Length Predicts Better Response of Patients with Advanced Non-small Cell Lung Cancer to EGFR Tyrosine Kinase Inhibitor.
Chen B; Luo J; Gu W; Shen L; Wang H; Zhou S
Cell Biochem Biophys; 2015 Dec; 73(3):799-804. PubMed ID: 27259328
[TBL] [Abstract][Full Text] [Related]
5. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.
Nomura M; Shigematsu H; Li L; Suzuki M; Takahashi T; Estess P; Siegelman M; Feng Z; Kato H; Marchetti A; Shay JW; Spitz MR; Wistuba II; Minna JD; Gazdar AF
PLoS Med; 2007 Apr; 4(4):e125. PubMed ID: 17455987
[TBL] [Abstract][Full Text] [Related]
7. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
[TBL] [Abstract][Full Text] [Related]
8. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
9. Lack of evidence for prognostic value of epidermal growth factor receptor intron-1 CA repeats for oral carcinomas.
Precht C; Blessmann M; Kluwe L; Scheld T; Schön G; Henningsen A; Pflug C; Smeets R; Heiland M; Gröbe A
Eur J Oral Sci; 2017 Apr; 125(2):95-101. PubMed ID: 28150908
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.
Ma F; Sun T; Shi Y; Yu D; Tan W; Yang M; Wu C; Chu D; Sun Y; Xu B; Lin D
Lung Cancer; 2009 Oct; 66(1):114-9. PubMed ID: 19201048
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
Liu G; Gurubhagavatula S; Zhou W; Wang Z; Yeap BY; Asomaning K; Su L; Heist R; Lynch TJ; Christiani DC
Pharmacogenomics J; 2008 Apr; 8(2):129-38. PubMed ID: 17375033
[TBL] [Abstract][Full Text] [Related]
14. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
15. Inverse relationship between the length of the EGFR CA repeat polymorphism in lung carcinoma and protein expression of EGFR in the carcinoma.
Suzuki M; Kageyama S; Shinmura K; Okudela K; Bunai T; Nagura K; Igarashi H; Kiyose S; Mori H; Tao H; Goto M; Takamochi K; Mochizuki T; Suzuki K; Ohashi R; Ogawa H; Yamada T; Niwa H; Tsuneyoshi T; Sugimura H
J Surg Oncol; 2008 Nov; 98(6):457-61. PubMed ID: 18683191
[TBL] [Abstract][Full Text] [Related]
16. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
18. Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.
Takenaka T; Takenoyama M; Yamaguchi M; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Yoshida T; Shiraishi Y; Morodomi Y; Hirai F; Taguchi K; Shimokawa M; Seto T; Ichinose Y
Eur J Cardiothorac Surg; 2015 Mar; 47(3):550-5. PubMed ID: 24894095
[TBL] [Abstract][Full Text] [Related]
19. EGFR: a prognostic and/or a predictive marker?
Hirsch FR
J Thorac Oncol; 2006 Jun; 1(5):395-7. PubMed ID: 17409888
[No Abstract] [Full Text] [Related]
20. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]